| 1. Reynolds JM, El Bissati K, Brandenburg J, Günzl A, Mamoun CB. (2007) Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B.. BMC Clin Pharmacol, 7 (3): (13). [PMID:17956613] |
| 2. Ciechanover A. (2005) Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture).. Angew Chem Int Ed Engl, 44 (37): (5944-67). [PMID:16142822] |
| 3. Groll M, Berkers CR, Ploegh HL, Ovaa H. (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.. Structure, 14 (3): (451-6). [PMID:16531229] |
| 4. Bonvini P, Zorzi E, Basso G, Rosolen A. (2007) Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.. Leukemia, 21 (4): (838-42). [PMID:17268529] |
| 5. Nakamura H, Watanabe M, Ban HS, Nabeyama W, Asai A. (2009) Synthesis and biological evaluation of boron peptide analogues of Belactosin C as proteasome inhibitors.. Bioorg Med Chem Lett, 19 (12): (3220-4). [PMID:19428245] |
| 6. Zhang H, Liu Z, Huang L, Hou J, Zhou M, Huang X, Hu W, Liu Z. (2017) The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis.. Lupus, 26 (9): (952-958). [PMID:28059023] |
| 7. Mazepa MA, Raval JS, Moll S, Ma A, Park YA. (2014) Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.. Br J Haematol, 164 (6): (900-2). [PMID:24345005] |
| 8. Wang Y, Zhou W, Zhang Z. (2015) Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient.. Rheumatology (Oxford), 54 (1): (194-5). [PMID:25288787] |
| 9. Jakez-Ocampo J, Atisha-Fregoso Y, Llorente L. (2015) Refractory primary Sjögren syndrome successfully treated with bortezomib.. J Clin Rheumatol, 21 (1): (31-2). [PMID:25539431] |
| 10. Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A et al.. (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.. Ann Rheum Dis, 74 (7): (1474-8). [PMID:25710470] |
| 11. Xie SC, Gillett DL, Spillman NJ, Tsu C, Luth MR, Ottilie S, Duffy S, Gould AE, Hales P, Seager BA et al.. (2018) Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.. J Med Chem, 61 (22): (10053-10066). [PMID:30373366] |
| 12. Kao CC et al.. (2022) Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules.. Mol Ther Nucleic Acids, 27 (335-348). [PMID:35024245] |
| 13. Abdin SM et al.. (2021) Nuclear factor-?B signaling inhibitors revert multidrug-resistance in breast cancer cells.. Chem Biol Interact, 340 (109450). [PMID:33775688] |
| 14. Gain C et al.. (2020) Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway.. PLoS Pathog, 16 (2): (e1008105). [PMID:32092124] |
| 15. Jianhao Liu, Xiaoman Xu, Yanying Li, Jingxia Xu, Ruogang Zhao, Siwei Liu, Jingliang Wu, Li Zhang, Bo Zhang. (2023) Bortezomib-loaded mixed micelles realize a “three-in-one” effect for enhanced breast cancer treatment. Biomaterials Science, 11 (14): (4890-4906). [PMID:37306225] |
F2215351